Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Organon (OGN) Just Overtook the 20-Day Moving Average

CALGARY, Alberta--(BUSINESS WIRE)--Matt Sjogren, President of CUPE 37 (City of Calgary outside workers) issued the following statement after employees rejected a contract settlement offer. Last night, the members of CUPE 37 rejected a memorandum of settlement of 9% wage increases over a three-year period. This vote sends a strong and clear message to the City of Calgary about the severe impact of inflation on our members. City employees are facing unprecedented financial challenges. Many are st.

CUPE 37 Members Reject City of Calgary Wage Package

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $OGN #denosumabbiosimilar--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Agnico Eagle Mines

Royal Caribbean Cruises

Sprouts Farmers Markets

Vital Farms, Inc.

VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.

5 Relative Price Strength Stocks With Strong Return Potential

Frontline

Western Union

Since it's becoming difficult to downplay the idea of stagflation, investors should place their bets on ultra-safe stocks such as Western Union (WU), Frontline (FRO) and Organon (OGN).

Is Stagflation Round the Corner? 3 Ultra-Safe Picks

Organon (OGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Organon (OGN) Stock

Mr. Cooper Group Inc

Office Depot

OGN, ODP and ASC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 13, 2024.

Best Value Stocks to Buy for May 13th

Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff has been eye-catching, climbing over 40% YTD, and likely indicates changing sentiment. Independent from Merck, Organon is micromanaging for profit & growth, the products and global footprint that had been undermanaged by MRK.

Organon Graduates From Spinoff Skepticism, With A Yield Above 5%

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women's health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the “Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “Unsecu.

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

OGN has underperformed its healthcare peers and the benchmark over the past year, but this could change going forward. The company's dominant women's health product- Nexplanon is looking at double-digit growth in sales this year, even as market loss exclusivity fears have been ameliorated. OGN is on course to generate over $1bn of adjusted FCF this year, and it could play a key role in bringing down the leverage to 3.5-4x.

Four Reasons Why Organon Stock Is A Good Buy

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women's health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the “secured notes”) and $500 million of senior unsecured notes due 2034 (the “un.

Organon Announces Proposed $1.0 Billion Senior Notes Offering

Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Organon (OGN) a New Buy Stock

Organon & Co. (NYSE:OGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Jane Marie - BNP Paribas Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Thank you for standing by. My name is Mandeep and I'll be your operator today.

Organon & Co. (OGN) Q1 2024 Earnings Call Transcript

Organon (OGN) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago.

Organon (OGN) Tops Q1 Earnings and Revenue Estimates

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Results for the First Quarter Ended March 31, 2024.

Organon Reports Results for the First Quarter Ended March 31, 2024

Affirm

Dominion Energy

GlaxoSmithKline

Innovative Industrial Properties

Kaiser Aluminum

Sunoco

Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024

Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.

Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?

DaVita

Roivant Sciences Ltd

Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks.

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Stay Ahead of the Game With Organon (OGN) Q1 Earnings: Wall Street's Insights on Key Metrics

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline

Organon (OGN) reachead $18.71 at the closing of the latest trading day, reflecting a +1.03% change compared to its last close.

Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Organon (OGN) stood at $18, denoting a +1.01% change from the preceding trading day.

Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know

Iron Mountain

With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).

Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks

In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.

Why the Market Dipped But Organon (OGN) Gained Today

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024.

News for Organon & Co Stock (OGN)